Pharmaceutical compositions comprising pore-forming proaerolysin protein (PRX302)
The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.
1. A pharmaceutical composition, comprising:
i) PRX302,
wherein said PRX302 comprises an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4, which maintains the ability to selectively target and kill normal prostate cells, and which comprises an affinity tag;
ii) one or more additional treatments for prostatitis; and
iii) a pharmaceutically acceptable carrier, diluent, excipient, and/or adjuvant.
2. The pharmaceutical composition of claim 1 , wherein said affinity tag is a C-terminal affinity tag.
3. The pharmaceutical composition of claim 2 , wherein said C-terminal affinity tag is a polyhistidine tag.
4. The pharmaceutical composition of claim 3 , wherein said C-terminal polyhistidine includes six histidine residues.
5. The pharmaceutical composition of claim 4 , wherein said one or more additional treatments for prostatitis is selected from the group consisting of a neuromodulator, a muscle relaxant, an antibiotic, an anti-inflammatory agent.
6. The pharmaceutical composition of claim 5 , wherein said antibiotic is fluoroquinolone or trimethoprim-sulfamethoxazole.
7. The pharmaceutical composition of claim 5 , formulated for transrectal, transurethral, transperineal, transdermal, intraprostatic, parenteral, topical, or oral administration, or administration by inhalation or spray.
8. The pharmaceutical composition of claim 7 , wherein said parenteral administration is intravenous, intramuscular, subcutaneous, intrathecal, intrasternal, or by infusion.